MA42535A - Constructions d'anticorps bispécifiques se liant à la mésothéline et à cd3 - Google Patents

Constructions d'anticorps bispécifiques se liant à la mésothéline et à cd3

Info

Publication number
MA42535A
MA42535A MA042535A MA42535A MA42535A MA 42535 A MA42535 A MA 42535A MA 042535 A MA042535 A MA 042535A MA 42535 A MA42535 A MA 42535A MA 42535 A MA42535 A MA 42535A
Authority
MA
Morocco
Prior art keywords
mesothelin
constructions
bispecific antibodies
antibodies binding
binding
Prior art date
Application number
MA042535A
Other languages
English (en)
Other versions
MA42535B1 (fr
Inventor
Jonas Anlahr
Julie Bailis
Claudia Bluemel
Patrick Hoffmann
Peter Kufer
Elisabeth Nahrwold
Doris Rau
Tobias Raum
Original Assignee
Amgen Inc
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res Munich Gmbh filed Critical Amgen Inc
Priority claimed from PCT/EP2016/068304 external-priority patent/WO2017021356A1/fr
Publication of MA42535A publication Critical patent/MA42535A/fr
Publication of MA42535B1 publication Critical patent/MA42535B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA42535A 2015-07-31 2016-08-01 Constructions d'anticorps bispécifiques se liant à la mésothéline et à cd3 MA42535B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199939P 2015-07-31 2015-07-31
PCT/EP2016/068304 WO2017021356A1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps bispécifiques se liant à la mésothéline et à cd3

Publications (2)

Publication Number Publication Date
MA42535A true MA42535A (fr) 2018-06-06
MA42535B1 MA42535B1 (fr) 2024-01-31

Family

ID=60245272

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42535A MA42535B1 (fr) 2015-07-31 2016-08-01 Constructions d'anticorps bispécifiques se liant à la mésothéline et à cd3

Country Status (2)

Country Link
AR (1) AR105560A1 (fr)
MA (1) MA42535B1 (fr)

Also Published As

Publication number Publication date
MA42535B1 (fr) 2024-01-31
AR105560A1 (es) 2017-10-18

Similar Documents

Publication Publication Date Title
MA54514A (fr) Anticorps se liant à cd3
MA42530A (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA49038A (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
MA41279A (fr) Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux
MA43959A (fr) Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
EP3512549A4 (fr) Anticorps se liant à cd3
MA51734A (fr) Anticorps se liant à gprc5d
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3634995A4 (fr) Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
MA55043A (fr) Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
MA45680A (fr) Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
MA43305A (fr) Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA43658A (fr) Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation
MA46893A (fr) Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation
DK3411402T3 (da) Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA71419A (fr) Anticorps se liant à egfr et cmet
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP3408293A4 (fr) Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
MA44054A (fr) Plateforme d'anticorps bispécifique